Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2022-10-17
2025-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The Phase 2 portion of the study will consist of an expansion cohort of up to 39 patients receiving HCW9218 monotherapy at the RP2D level. An additional independent Phase 2 cohort of patients receiving HCW9218 at the RP2D level in sequence with gemcitabine and nab-paclitaxel will also be considered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HCW9218
Experimental Arm: HCW9218
HCW9218
Bifunctional TGF-β antagonist/IL-15 protein complex
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCW9218
Bifunctional TGF-β antagonist/IL-15 protein complex
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For dose escalation phase (Phase 1b), distant metastatic disease or advanced disease and not a candidate for down staging to resection For expansion phase (Phase 2), distant metastatic disease only
3. Prior radiation is allowed if the index lesion(s) remains outside of the treatment field or has progressed since prior treatment. Radiation therapy must have been completed at least 4 weeks prior to the baseline scan.
4. Age \> 18 years
5. A life expectancy of at least 12 weeks
6. Laboratory tests performed within 14 days of treatment start:
1. Absolute neutrophil count (AGC/ANC) ≥ 1,500/μL (≥1.5 × 109/L)
2. Platelets ≥ 100,000/μL (≥ 100 × 109/L) \[Subjects may be transfused not more than 1 unit of platelets within 2 weeks to meet this requirement\]
3. Hemoglobin ≥ 9 g/dL (\>90g/L) \[Subjects may be transfused not more than 2 units of pRBCs within 2 weeks to meet this requirement\]
4. Calculated glomerular filtration rate (GFR)\* \>40 mL/min OR serum creatinine ≤ 1.5 × ULN
5. Total bilirubin ≤ 2.0 × ULN or ≤ 3.0 × ULN for subjects with Gilbert's syndrome
6. AST, ALT, ALP ≤ 2.5 × ULN or ≤ 5.0 × ULN if liver metastasis present \*using the following Cockcroft \& Gault equation to calculate the eGFR for this study.
eGFR in mL/min = \[(140-age in years) × (weight in kg) × F\]/(serum creatinine in mg/dL × 72), where F =1 if male; and 0.85 for female.
7. Adequate pulmonary function with PFTs \> 50% FEV1 if symptomatic or prior known impairment
8. Negative serum pregnancy test within 14 days of treatment start if female and of childbearing potential (non-childbearing is defined as greater than one year postmenopausal or surgically sterilized)
9. Female subjects of childbearing potential must adhere to using a medically accepted method of birth control prior to screening and agree to continue its use for at least 28 days after the last dose of HCW9218 or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use a barrier method of birth control and agree to continue its use for at least 28 days after the last dose of HCW9218
10. Provide signed informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
Exclusion Criteria
1. History of clinically significant vascular disease, including any of the following within 6 months prior to start of study treatment: MI or unstable angina, percutaneous coronary intervention, bypass grafting, ventricular arrhythmia requiring medication, stroke or transient ischemic attack, symptomatic peripheral arterial disease
2. Marked baseline prolongation of QT/QTc interval (e.g., demonstration of a QTc interval greater than or equal to 470 milliseconds by Fridericia's correction)
3. Subjects with untreated CNS metastases are excluded. Subjects are eligible if CNS metastases are treated and subjects are neurologically stable for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent)
4. Anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment start
5. Other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the subject is currently in complete remission, or any other cancer from which the subject has been disease-free for 3 years after surgical treatment
6. Known hypersensitivity or history of allergic reactions attributed to compounds of similar chemical or biologic composition to the agents used in the study
7. Prior therapy with TGF-β antagonist, IL-15 or analogs
8. Concurrent herbal or unconventional therapy (e.g., St. John's Wort)
9. Known autoimmune disease requiring active treatment. Subjects s with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
10. Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy.
11. Prior organ allograft or allogeneic transplantation
12. Known HIV-positive or AIDS
13. Women who are pregnant or nursing
14. Any ongoing toxicity from prior anti-cancer treatment that, in the judgment of the Investigator, may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than peripheral neuropathy, alopecia, and fatigue must resolve to grade 1 (NCI CTCAE v5.0) or baseline before administration of the study treatment
15. Psychiatric illness/social situations that would limit compliance with study requirements
16. Other illness or a medical issue that in the opinion of the Investigator would exclude the subject from participating in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ImmunityBio, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paula Bradshaw, MSN, MBA, RN
Role: STUDY_DIRECTOR
VP, Clinical Business Operations
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HonorHealth
Scottsdale, Arizona, United States
National Institute of Health/ National Cancer Institute
Bethesda, Maryland, United States
Washington University in St. Louis
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCWPAN102
Identifier Type: -
Identifier Source: org_study_id